comparemela.com

Latest Breaking News On - Verona pharma - Page 2 : comparemela.com

Viking, CRISPR, Cytokinetics are M&A targets: Wells Fargo

Viking, CRISPR, Cytokinetics are M&A targets: Wells Fargo
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Moonlake-immunotherapeutics
Arcutis-biotherapeutics
Zealand-pharma
Verona-pharma
Bridgebio-pharma
Mohit-bansal
Neurocrine-biosciences
Iovance-biotherapeutics
Wells-fargo
Alnylam-pharmaceuticals
Rhythm-pharmaceuticals
Apellis-pharmaceuticals

24-week ensifentrine improves dyspnea in moderate to severe COPD

24-week ensifentrine improves dyspnea in moderate to severe COPD
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United-states
San-diego
California
American
Verona-pharma
Kristen-dowd
Donalda-mahler
Byisabella-hornick
Dartmouth-university
American-thoracic-society-international-conference
Transitional-dyspnea-index
American-thoracic-society-international

Dupixent data enhance Sanofi, Regeneron's pursuit of COPD nod

Sanofi and Regeneron provided trial results which bolster their pursuit of an FDA approval to treat chronic obstructive pulmonary disease.

San-diego
California
United-states
American
Surya-bhatt
Verona-pharma
University-of-alabama-at-birmingham
Amgen
American-thoracic-society
Astrazeneca

Head to Head Contrast: Verona Pharma (NASDAQ:VRNA) and Vectura Group (OTCMKTS:VEGPF)

Vectura Group (OTCMKTS:VEGPF – Get Free Report) and Verona Pharma (NASDAQ:VRNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Risk & Volatility Vectura Group has a […]

United-states
United-kingdom
Switzerland
Chippenham
Wiltshire
Germany
France
London
City-of
America
David-anthony-gough
Verona-pharma

HC Wainwright Cuts Verona Pharma (NASDAQ:VRNA) Price Target to $30.00

Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective cut by HC Wainwright from $33.00 to $30.00 in a research note published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Verona Pharma’s FY2024 earnings at ($1.36) EPS, Q1 2025 earnings at ($0.24) […]

Piper-sandler
Verona-pharma
Kathleena-rickard
Sei-investments-co
Securities-exchange-commission
A-davidson
Campbell-co-investment-adviser
Capital-management
Cape-investment-advisory-inc
Free-report
Pharma-stock-down
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.